Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
9
|
| pubmed:dateCreated |
1989-9-27
|
| pubmed:abstractText |
Thirty-four patients with locally advanced, nonresectable gastric cancer (staged by laparotomy) received etoposide, Adriamycin (doxorubicin; Adria Laboratories, Columbus, OH), and cisplatin (EAP). Thirty-three patients were evaluable for response and toxicity. Second-look surgery with removal of residual tumor by gastrectomy and lymphadenectomy was performed in case of complete/partial remission (CR/PR) after EAP. After successful resection (R0- and R1-resection), two cycles of EAP were administered for consolidation therapy. Patients refusing reoperation received up to six cycles of EAP. The response rate (CR/PR) after EAP was 70% (23/33), including a 21% (7/33) rate of clinical CRs (CCRs). Two patients had minor remission (MR)/no change and seven had progressive disease. There was one early death. Nineteen of 23 responders (5 CCRs, 14 clinical PRs [CPRs]) and one patient with MR underwent second-look surgery. Five CCRs were pathologically confirmed; 10 patients with CPR were without evidence of disease (NED) after resection. In three patients (CPR), R1-resections (microscopically tumor-cell positive proximal margin) were performed; two patients are disease-free, 22+ and 33+ months after consolidation chemotherapy. In two patients, the tumor was again considered nonresectable. Twenty patients were disease-free after EAP +/- surgery +/- consolidation chemotherapy. Toxicity was primarily hematologic. Leukopenia and thrombocytopenia of World Health Organization (WHO) grade 3 occurred in 30% and 9%, respectively and grade 4 in 18% and 9% of the patients, respectively. There was no increased peri- or postoperative morbidity. After a median follow-up of 20 months for disease-free patients, the relapse rate is 60% (12/20). The median survival time for all patients is 18 months and for disease-free patients 24 months. EAP is highly effective in locally advanced gastric cancer, and offers a chance for surgery with curative intention in patients with an otherwise fatal prognosis.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Sep
|
| pubmed:issn |
0732-183X
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
7
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
N
|
| pubmed:pagination |
1318-26
|
| pubmed:dateRevised |
2006-4-24
|
| pubmed:meshHeading |
pubmed-meshheading:2769330-Adult,
pubmed-meshheading:2769330-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:2769330-Cisplatin,
pubmed-meshheading:2769330-Combined Modality Therapy,
pubmed-meshheading:2769330-Doxorubicin,
pubmed-meshheading:2769330-Drug Evaluation,
pubmed-meshheading:2769330-Etoposide,
pubmed-meshheading:2769330-Female,
pubmed-meshheading:2769330-Gastrectomy,
pubmed-meshheading:2769330-Humans,
pubmed-meshheading:2769330-Laparotomy,
pubmed-meshheading:2769330-Lymph Node Excision,
pubmed-meshheading:2769330-Male,
pubmed-meshheading:2769330-Middle Aged,
pubmed-meshheading:2769330-Neoplasm Staging,
pubmed-meshheading:2769330-Remission Induction,
pubmed-meshheading:2769330-Reoperation,
pubmed-meshheading:2769330-Stomach Neoplasms
|
| pubmed:year |
1989
|
| pubmed:articleTitle |
Preoperative chemotherapy in locally advanced and nonresectable gastric cancer: a phase II study with etoposide, doxorubicin, and cisplatin.
|
| pubmed:affiliation |
Department of Hematology/Oncology, Hannover University, Medical School, West Germany.
|
| pubmed:publicationType |
Journal Article
|